Research
Hormonal
SGLT2 inhibitors provide significant cardiovascular and renal protection in type 2 diabetes patients through mechanisms independent of glycemic control, including metabolic reprogramming and fuel switching.
If you have type 2 diabetes, ask your doctor about SGLT2 inhibitors. They protect your heart and kidneys through mechanisms beyond just lowering blood sugar, such as helping your body use different fuels. This can significantly reduce your risk of serious complications.
GoodSupportsHIGH confidence
SGLT2i have shown impressive effects on mortality and cardiovascular and renal morbidity in randomized clinical trials in both diabetic and non-diabetic patients... suggesting that much of these salutary effects are not mediated by changes in glycemia... SGLT2i possess many pleiotropic properties, besides promoting glucosuria, e.g. metabolic reprogramming, fuel switching, remodeling cardiac structure, and enhancing myocardial metabolism by switching to ketones as fuels.
Why this rating
Based on multiple randomized clinical trials cited (Zinman, Neal, Wiviott) and a systematic review.
Source
Editorial: World diabetes day 2024: exploring mechanisms, innovations, and holistic approaches in diabetes care
Åke Sjöholm et al. · Frontiers in Endocrinology · 2026
DOI 10.3389/fendo.2026.1808396
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) provide superior renal protection compared to insulin in early-stage diabetic kidney disease by reducing CD36 levels and urinary albumin excretion.Moderate
- Maternal depression during pregnancy is significantly associated with an increased risk of gestational diabetes mellitus (GDM), suggesting that screening for depression may reduce GDM risk.Moderate
- Formula diet-based lifestyle interventions may lead to greater weight loss compared to modern antidiabetic drugs, while maintaining comparable long-term glycemic control in obese type 2 diabetes patients.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →